Liu Xiaomeng, Li Qin, Yan Xiao, Wang Lingling, Qiu Jiayue, Yao Xiaojun, Liu Huanxiang
Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao 99907, China.
J Chem Inf Model. 2025 Apr 14;65(7):3294-3308. doi: 10.1021/acs.jcim.5c00074. Epub 2025 Apr 2.
Kinases are critical regulators in numerous cellular processes, and their dysregulation is linked to various diseases, including cancer. Thus, protein kinases have emerged as major drug targets at present, with approximately a quarter to a third of global drug development efforts focusing on kinases. Additionally, deep learning-based molecular generation methods have shown obvious advantages in exploring large chemical space and improving the efficiency of drug discovery. However, many current molecular generation models face challenges in considering specific targets and generating molecules with desired properties, such as target-related activity. Here, we developed a specialized and enhanced deep learning-based molecular generation framework named KinGen, which is specially designed for the efficient generation of small molecule kinase inhibitors. By integrating reinforcement learning, transfer learning, and a specialized reward module, KinGen leverages a binding affinity prediction model as part of its reward function, which allows it to accurately guide the generation process toward biologically relevant molecules with high target activity. This approach not only ensures that the generated molecules have desirable binding properties but also improves the efficiency of molecular optimization. The results demonstrate that KinGen can generate structurally valid, unique, and diverse molecules. The generated molecules exhibit binding affinities to the target that are comparable to known inhibitors, achieving an average docking score of -9.5 kcal/mol, which highlights the model's ability to design compounds with enhanced activity. These results suggest that KinGen has the potential to serve as an effective tool for accelerating kinase-targeted drug discovery efforts.
激酶是众多细胞过程中的关键调节因子,其失调与包括癌症在内的各种疾病相关。因此,蛋白激酶目前已成为主要的药物靶点,全球约四分之一到三分之一的药物研发工作都聚焦于激酶。此外,基于深度学习的分子生成方法在探索广阔化学空间和提高药物发现效率方面显示出明显优势。然而,许多当前的分子生成模型在考虑特定靶点以及生成具有所需特性(如与靶点相关的活性)的分子时面临挑战。在此,我们开发了一个专门的、基于深度学习增强的分子生成框架,名为KinGen,它是专门为高效生成小分子激酶抑制剂而设计的。通过整合强化学习、迁移学习和一个专门的奖励模块,KinGen利用结合亲和力预测模型作为其奖励函数的一部分,这使其能够准确地将生成过程导向具有高靶点活性的生物学相关分子。这种方法不仅确保生成的分子具有理想的结合特性,还提高了分子优化的效率。结果表明,KinGen可以生成结构有效、独特且多样的分子。生成的分子对靶点的结合亲和力与已知抑制剂相当,平均对接分数达到-9.5千卡/摩尔,这突出了该模型设计具有增强活性化合物的能力。这些结果表明,KinGen有潜力成为加速激酶靶向药物发现工作的有效工具。